Ascendis Pharma A/S ASND 深 滬
已收盤 07-31 16:00:00 美东时间
243.91
-7.160
-2.85%
華盛通- 最 高252.46
- 今 開249.71
- 成交量 50.89万股
- 最 低 243.30
- 昨 收 251.07
- 總市值 159.99亿
- 52周最高 282.15
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 186.054
- 委 比 -1.39%
- 總股本 6559.28万
- 歷史最高 282.15
- 量 比 1.10
- 振 幅 3.65%
- 歷史最低 11.92
- 每 手 1
- 風險率 21.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ascendis Pharma Expands Yorvipath Into Adolescents, Raising Long-Term Growth Hopes
Ascendis Pharma A/S ($ASND) announced an update on their ongoing clinical study...
07-29 00:31
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275
Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $256 to $275.
07-24 02:05
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $275 to $280.
07-07 23:59
Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital
The latest update is out from Ascendis Pharma ( ($ASND) ). On June 29, 2026, As...
06-30 04:28
Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell Midcap
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution,...
06-27 04:03
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
Ascendis Pharma A/S has been added to several Russell U.S. Indexes, including the Russell 3000, 1000, 2500, and Midcap Indexes, effective June 26, 2026. These indexes track major U.S. equities and are widely used by investors. The company, a global biopharmaceutical firm, applies its TransCon technology to develop innovative therapies. For more information, visit their website or contact investor and media relations.
06-26 20:01
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
Ascendis Pharma announced that data from its clinical trials for treating children with achondroplasia will be presented at the 12th International Conference on Children's Bone Health in Montreal. Key highlights include Week 104 results from the ApproaCH Trial showing improvements in lower-extremity alignment with TransCon CNP (navepegritide) and Week 52 data from the COACH Trial on combination therapy with TransCon CNP and TransCon hGH (lonapegs...
06-25 20:01
Why Is Ascendis Pharma Stock Gaining Friday?
Ascendis Pharma A/S (NASDAQ:ASND) on Thursday reported five-year results from its Phase 2 PaTH Forward trial, showing that TransCon PTH (palopegteriparatide) delivered sustained efficacy and safety in adults with hypoparathyroidism. The stock rose in Friday trading following the announcement. The Pa...
06-13 00:29
